CHICAGO, July 28 (Xinhua) — Northwestern Medicine has launched a COVID-19 Prevention Trials Registry for people who are interested in participating in COVID-19 clinical trials to prevent infection from the virus, according to a news release posted on the website of Northwestern University (NU) on Monday.
The goal is to recruit 5,000 individuals for the COVID Prevention Trials Registry. Individuals being sought are 18 years and older and working in a job that puts them at higher risk of exposure to the virus. This includes health care workers, people who work in a grocery store or retail outlet, public transportation employees, factory or plant workers, and individuals who live or work in congregated living facilities like nursing homes.
The registry also needs members of the community who are disproportionately affected by COVID-19 such as older persons, racial/ethnic groups like African Americans, Latin and Native Americans and people with certain underlying health conditions.
Participants in the registry will be contacted when an appropriate study based on their health profile is being conducted.
The first study, expected to launch in August, will be a Phase 3 trial investigating the new AstraZeneca LLC vaccine drug candidate. Results of the Phase 1 and 2 trial of the drug were published in The Lancet journal last week, showing the drug was safe and boosted antibody responses.
Northwestern Medicine is the collaboration between Northwestern Memorial HealthCare and NU Feinberg School of Medicine, which includes research, teaching and patient care. Enditem